Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunotherapy in Hepatocellular Cancer Patients with Mild to Severe Liver Dysfunction: Adjunctive Role of the ALBI Grade
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 7, Pages 1862
Publisher
MDPI AG
Online
2020-07-10
DOI
10.3390/cancers12071862
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Molecular therapies for HCC: Looking outside the box
- (2020) Sandrine Faivre et al. JOURNAL OF HEPATOLOGY
- Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
- (2020) Pei-Chang Lee et al. Cancers
- Immune-based therapies for hepatocellular carcinoma
- (2020) David J. Pinato et al. ONCOGENE
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2019) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab in patients with advanced hepatocellular carcinoma and Child‐Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series
- (2019) Swetha Kambhampati et al. CANCER
- Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study
- (2019) Kazuomi Ueshima et al. Cancers
- Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients
- (2019) Francesco Tovoli et al. JOURNAL OF HEPATOLOGY
- 747PA phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
- (2019) J Llovet et al. ANNALS OF ONCOLOGY
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- LBA3IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
- (2019) A-L Cheng et al. ANNALS OF ONCOLOGY
- Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms
- (2019) Petros Fessas et al. IMMUNOLOGY
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Application of the Albumin-Bilirubin Grade in Predicting the Prognosis of Patients With Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
- (2019) Lin Xu et al. TRANSPLANTATION PROCEEDINGS
- Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond
- (2018) Jean-Luc Raoul et al. CANCER TREATMENT REVIEWS
- Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
- (2018) Richard S. Finn et al. JOURNAL OF HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Challenges and opportunities in the clinical development of immune checkpoint inhibitors for hepatocellular carcinoma
- (2018) Michael J Flynn et al. HEPATOLOGY
- Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use
- (2017) Yuan-Hung Kuo et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma
- (2017) David J. Pinato et al. JOURNAL OF HEPATOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis
- (2017) Alessandro Granito et al. LANCET ONCOLOGY
- Validation of the albumin-bilirubin grade-based integrated model as a predictor for sorafenib-failed hepatocellular carcinoma
- (2017) Pei-Chang Lee et al. LIVER INTERNATIONAL
- Medical Management of Hepatocellular Carcinoma
- (2017) Nicole E. Rich et al. Journal of Oncology Practice
- Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization
- (2017) Bin Gui et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Complete Response of Hepatocellular Carcinoma in a Patient With End-stage Liver Disease treated With Nivolumab: Whishful thinking or Possible?
- (2016) Joerg Trojan et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Integration of albumin-bilirubin (ALBI) score into Barcelona Clinic Liver Cancer (BCLC) system for hepatocellular carcinoma
- (2016) Anthony W H Chan et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma
- (2016) Anna Pecorelli et al. LIVER INTERNATIONAL
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
- (2015) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib
- (2015) Alessandro Granito et al. Therapeutic Advances in Gastroenterology
- The ART Score Is Not Effective to Select Patients for Transarterial Chemoembolization Retreatment in an Italian Series
- (2014) Eleonora Terzi et al. DIGESTIVE DISEASES
- Cirrhosis-associated immune dysfunction: Distinctive features and clinical relevance
- (2014) Agustín Albillos et al. JOURNAL OF HEPATOLOGY
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Immunotherapy of hepatocellular carcinoma
- (2012) Angela D. Pardee et al. OncoImmunology
- Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies
- (2009) Puneeta Tandon et al. LIVER INTERNATIONAL
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now